Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 1631
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 4  |  Issue : 1  |  Page : 9-12

Chromophobe renal cell carcinoma: Comprehensive analysis of 11 cases


1 Department of Urology, KLES Kidney Foudation, Belgaum, India
2 Department of Biotechnology and Microbiology, Karnatak University, Dharwad, Karnataka, India

Correspondence Address:
Shridhar C Ghagane
Department of Biotechnology and Microbiology, Karnatak University, Dharwad, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-0513.149023

Rights and Permissions

Background: Chromophobe renal cell carcinoma (chRCC) is a subtype of RCC. chRCC is diagnosed mainly in sixth decade of life. An incidence of chRCC is similar in both men and woman. Eighty-six percent of chRCCs cases are diagnosed in early stages. To analyze the clinical behavior of chRCC, we retrospectively evaluated the data from our hospital. The aim of this study was to evaluate the incidence, clinical presentation, prognosis, and clinical outcome of chRCC in a retrospective series of nephrectomy specimens. Materials and Methods: We retrospectively looked at our hospital database, which included 318 patients who had undergone surgery for RCC between January 2000 and December 2013. Several parameters were noted in each patient, which included age, sex, symptoms at presentation, Eastern Cooperative Oncology Group performance status, tumor diameter, tumor node metastasis stage and grade, histologic cell type, follow-up time, local recurrence, disease progression, and death. Results: Of 318 patients included in the database, 11 (3.45%) had chRCC. Preoperatively, 9 (81%) had T1 lesions, and the remaining 2 (18.9%) had T2 lesions. Of the T1 lesions, 6 had tumors ≤4 cm (T1a) in diameter and the remaining 3 had tumors >4 cm (T1b) in diameter. The mean survival of the patients was 99.27 ΁ 27 months. Conclusions: Our series confirms a favorable outcome for the chRCC subtype with little local aggressiveness and a low propensity for progression and death from cancer.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5286    
    Printed59    
    Emailed0    
    PDF Downloaded77    
    Comments [Add]    

Recommend this journal